Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...

While a federal judge has paused the funding cuts, the uncertainty has researchers concerned about the future of scientific ...

Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%.

Franklin College unveils its top 5 and bottom 5 for the 2025 USA TODAY Ad Meter Marketing Spotlight. See which Super Bowl ads ...

The United States is seeing a second peak in flu cases this season. After doctor’s office visits for flu dipped early this ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Presented in partnership with the Perricelli-Gegnas Center for Entrepreneurship & Innovation, O'Leary will appear in the Weis ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

(Reuters) -U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strong sales of ...

COVID products are still a profit driver for the company. Pfizer is forecast by Wall Street to report $5.3 billion in 2024 ...

which includes Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy as well as Pfizer's cancer drugs Ibrance and Xtandi. Negotiated prices for these drugs, which are ...